HIT Consultant reports on the partnership between Scipher Medicine and Atropos Health to improve precision medicine for rheumatoid arthritis (RA) patients. This collaboration will combine Scipher’s unique data from their PrismRA test, which predicts treatment response, with Atropos Health’s real-world evidence (RWE) generation tools. By integrating this data, personalized treatment decisions and improved outcomes for patients with RA are expected.
“PrismRA®, a groundbreaking blood test, is revolutionizing the treatment of rheumatoid arthritis (RA), a condition affecting 20 million people globally. Through a simple blood draw, PrismRA analyzes an individual’s molecular signature to identify patients unlikely to respond adequately to TNFi therapy, the world’s top-selling drug class. This enables clinicians to prescribe more effective alternative therapies, minimizing unnecessary dose escalations or cycles of ineffective treatment.
In collaboration with Atropos Health, PrismRA’s molecular insights will be integrated into the Atropos Evidence™ Network, expanding access to advanced, artificial intelligence (AI)-powered evidence generation tools such as Green Button™ and ChatRWD™—the first AI-driven chat-to-database application in healthcare. These tools deliver real-world evidence within minutes, empowering clinicians with actionable data to support shared decision-making.”